2 min read
When a company receives an observation from INVIMA following a quality system inspection, the most common reaction is to look for the documentation gap — the missing record, the incomplete procedure, the unapproved change. What is harder to see, and far more consequential, is that the observation rarely originates from a missing document. It originates from a system that was built for a different kind of evaluation.
GMP compliance and QMS coherence are not the same thing. Most pharmaceutical operations know the first well. Far fewer have calibrated the second to how INVIMA reads it.
Where the assumption breaks
The standard preparation logic for a regulatory inspection goes like this: ensure GMP compliance, document it thoroughly, and the inspection should proceed without significant findings. That logic holds for many agencies. INVIMA's QMS audit introduces a different evaluation layer.
What INVIMA evaluates in a quality system audit is not limited to whether procedures exist and are followed. The agency examines whether the quality system operates as a coherent whole — whether the connections between process design, change control, deviation management, supplier qualification, and CAPA are functioning as an integrated system rather than as a collection of compliant documents.
A company can have every required SOP in place, every record signed and dated, and still generate observations — because the system lacks the internal logic INVIMA expects to find when it evaluates how quality decisions are made, escalated, and resolved over time.
The gap list is evidence — the systemic misread is the argument
Companies that have gone through a QMS audit in Colombia under INVIMA's framework report a consistent pattern: the observations they received were traceable not to individual documentation failures, but to structural gaps in how the system was designed to function under local regulatory expectations.
The most frequently surfaced gaps include disconnects between change control logic and post-approval variation management, CAPA systems that close findings without demonstrating systemic resolution, and quality oversight structures that meet GMP requirements on paper but cannot demonstrate operational integration under INVIMA's audit methodology. Each of these is, individually, a correctable gap. Together, they are a signal that the system was calibrated for a different inspection standard.
For companies preparing proactively, this distinction matters before the audit begins. The preparation question is not 'are our procedures in order' but 'does our system demonstrate the kind of coherence INVIMA expects to see functioning in practice.' Those are different preparation exercises — and they lead to different outcomes.
What a QMS audit in Colombia actually requires
An INVIMA QMS audit evaluates the quality system against a framework that combines GMP requirements with local regulatory expectations around operational accountability, lifecycle integrity, and systemic evidence of continuous improvement. The audit is not a checklist review. It is a system of coherence assessment.
That means the preparation is strategic, not administrative. Companies that arrive to an INVIMA inspection having mapped their quality system against the agency's local evaluation logic — not just against an international GMP standard — consistently navigate the process with fewer observations and shorter resolution cycles.
The companies that don't are not necessarily less compliant. They are less prepared for the specific way INVIMA reads compliance.
Freyr's QMS audit support in Colombia helps global pharmaceutical companies evaluate their quality systems against INVIMA's local inspection framework — before the audit, not in response to its findings. If you are preparing for an INVIMA inspection or have received observations you need to resolve, contact us to assess your QMS readiness.
